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Background: The administration of anesthetics determines depression of the central nervous system and general
anesthesia by inhalation may cause an environmental pollution of the operating rooms. It may therefore conceive a
possible occupational etiology of Parkinson's Disease (PD).
Case presentation: In a Caucasian male aged 59 years, PD was diagnosed by brain scans with a presynaptic
radioactive tracer of the dopaminergic system. Family history was negative for Parkinson’s disease or essential
tremor. He was a smoker, a moderate consumer of coffee and alcohol, and never exposed to pesticides/metals. For
30 years (since the age of 29 until today), he worked as an anesthesiologist in private clinics in the Veneto
(Northern Italy), exposed to anesthetic gases. The time elapsed from first exposure to onset of disease is 22 years,
fulfilling the requirement of the induction/latency period. A literature search demonstrated unacceptable levels of
anesthetic gases in public hospitals of the Veneto region from 1990 to 1999. This exposure was presumably high
also in private hospitals of the region until at least 2007, when an overexposure to sevoflurane was repeatedly
measured in this patient. The association between occupational exposure to anesthetic gases and risk of Parkinson’s
disease was supported by a case-control study (reporting a two-fold increase in the risk of PD associated
with a clinical history of general anesthesia) and a cohort study comparing mortality from PD between US
anesthesiologists and internists (showing a statistically significant excess (p=0.01) in anesthesiologists compared to
internists). Numerous recent mechanistic studies (in vitro essays and in vivo short-term studies) strengthened the
association between exposure to anesthetic gases (nitrous oxide, halothane, isoflurane, levoflurane) and PD.
Conclusion: In view of the limited evidence of human studies and the sufficient evidence of experimental studies,
the high exposure to anesthetic gases could have induced PD in the subject under study.
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disease, CausalityBackground
The main structures involved in the development of
Parkinson’s Disease (PD) are the Substantia Nigra Pars
Compacta and Striate Nucleus of the central nervous
system (CNS), in which dopamine is the neuro-
transmitter molecule.
The administration of anesthetics determines their
distribution to the CNS and other tissues of the body.
The desired effect is the depression of the CNS that is
obtained in relation to the concentration achieved in this
tissue. It is believed that general anesthesia by inhalation
may cause an environmental pollution of the operating* Correspondence: giuseppe.mastrangelo@unipd.it
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distribution, and reproduction in any mediumrooms and create problems of occupational exposure in
operators. It may therefore conceive a possible occupa-
tional etiology of PD.
A case of Parkinson’s disease occurring in an anes-
thesiologist came recently to our attention. In order to
evidence an association between occupational exposure
to the agent and the disease, we made an extensive
search of the literature. First, the patient was visited to
confirm the diagnosis of PD and investigate the occupa-
tional exposure to volatile anesthetics.
Case presentation
The patient (male, Caucasian, aged 59 years) worked for
30 years as a free lance anesthesiologist in surgical
rooms of private clinics in the Veneto (North Easternntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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oxide (N2O) for 22 years (until 2005); halothane, isoflur-
ane, levoflurane and other halogenated aliphatic hydro-
carbons for seven years (1983-1990); and sevoflurane for
23 years (from 1990 until now). In his post-shift urine,
hexafluoroisopropanol (metabolite of sevoflurane) was
483.4 μg/liter (above the threshold of 465 μg/liter) in
May 2007 and 535.6 μg/liter in a separate working day
one week later.
The patient was born from a spontaneous delivery (his
mother was 28) and always had regular habits. In par-
ticular, he reported the consumption of 5-6 cigarettes/
day, half a liter/day of wine, 3 cups/day of coffee and tap
water only. He always carried out sport (football, tennis,
skiing). He denied environmental exposure to pesticides
or heavy metals (iron, copper, manganese, lead) and dis-
claimed past health problems such as high blood pres-
sure or vascular disorders, asthma, nor mood disorders,
trauma or surgical interventions. He experienced a knee
injury with lesion of cruciate ligaments (treated with
ibuprofen/piroxicam and several arthrocentesis). In
2006, following recurrent left lumbosciatalgia he under-
went nuclear magnetic resonance that demonstrated
medium grade spondylolisthesis. Neurological symptoms
of PD first appeared in 2005 and became progressively
worse, leading to neurology consultations and imaging
examinations. Brain magnetic resonance imaging was
negative. The single-photon emission computed tomog-
raphy (SPECT), with a radioactive presynaptic tracer of
the dopaminergic system (123I DatSCAN), showed “re-
duced concentration of the tracer in the basal ganglia on
the right and in the lenticular basal ganglia on the right
and left, supporting the clinical suspicion of PD”. The
subsequent treatment with dopaminergic drugs
reduced symptoms.
Exposure to anesthetic gases
The search of “occupational exposure”, “anesthetic
gases” and “Veneto” in PubMed and Scopus returnedTable 1 Anesthetist exposure to anesthetic gases (nitrous o
of the Veneto Region, 1990-2002, by personal sampling: su
deviation (in parts per million, ppm), percentage of measu
references








*environmental concentration values recalculated from the urine concentration.three citations [1-3]. Available exposure data, collected
with personal sampling in anesthesiologists in Veneto
public hospitals from 1990 to 1999, are shown in Table 1:
means and standard deviations as well as percentage
of exceedance with respect to a threshold of 50 ppm for
nitrous oxide and 2 ppm for forane. Exposure over time
decreased for N2O but not for forane. Compliance with
exposure threshold values was assessed with the “one-
sided tolerance limits” (OTL) test, which places the
statistic OTL (y-axis) against number of samples taken
(x-axis) [4]. As shown in Figure 1, all measures were
plotted in the unacceptable area.
Epidemiological and experimental research
Different combinations of “anesthesiologist”, “anesthetic
gases”, “nitrous oxide”, “halothane”, “isofluorane”, “sevo-
fluorane”, “Parkinson’s disease”, “dopamine”, “dopamin-
ergic neurons”, “substantia nigra”, “striatum”, “vitamin
B12”, “cobalamine”, “αβ–amyloid” were searched in
PubMed and Scopus.
An association between exposure to anesthetic gases
and PD was suggested for the first time by a case–con-
trol study conducted in Italy (136 patients diagnosed
with PD by a neurologist and 272 controls matched by
age and sex), in which the risk of PD was evaluated with
odds ratio (OR) and 95% confidence interval (CI) estimated
with logistic regression analysis. Smoking adjusted ORs
were: 41.7 (CI: 12.2–142.5; p <0.0001) for family history of
PD; 10.8 (2.6–43.7; p<0.0001) for family history of essential
tremors; 2.6 (1.4–3.7; p < 0.0013) for advanced maternal
age at the time of childbirth; 7.7 (1.4–44.1; p<0.0212) for
employment in agriculture; 2.0 (1.1–3.6; p < 0.0308) for the
use of well water; and 2.2 (1.3–3.8; p<0.0024) for general
anesthesia [5].
A cohort study compared mortality from PD between
two large groups of US male doctors (33,040 anesthesi-
ologists and 33,044 internists) that were followed up
from 1979 to 1995 [6]. The standardized mortality
ratio (SMR) was estimated separately in anesthesiologistsxide and isoflurane) measured in the operating rooms
rvey year, number of samples, mean and standard
rement exceeding the standard (Exceedance %), and

































Figure 1 Compliance of exposures to anesthetic gases with
exposure threshold values, assessed with the “one-sided tolerance
limits” (OTL) test: OTL on y-axis and number of samples on x-axis
of the OTL diagram.
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and, in each follow-up period, a risk ratio (RR) (ratio of
SMR anesthesiologists / SMR internists) was obtained.
Table 2 shows that in each group of doctors, mortality
was lesser with respect to that in the US population.
When the two groups were directly compared, RR be-
comes 3.47 (1.37–9.43) in the second period, a statistically
significant excess (p = 0.01) indicating that PD risk was
higher in anesthesiologists compared to internists [6].
The mechanistic studies linking exposure to anesthetic
gases to PD are reported below.
According to Brodsky [7] nitrous oxide inactivates
vitamin B12, which is the essential cofactor for the en-
zyme methionine synthetase. The latter favors the con-
version of homocysteine (HC) in methionine, which is
the precursor of S-adenosyl-methionine, a universal
methyl-group donor involved in the regulation of DNA
epigenetic processes [8]. The advent of sensitive diagnos-
tic tests, including HC assays, has revealed a surprisingly
high prevalence of a more subclinical form of B12 defi-
ciency (without anemia), particularly in operating theatre
staff exposed to high level of N2O [9]. Metabolic evi-
dence of B12 deficiency was reported in association with
several neurodegenerative disorders, including Parkin-
son’s disease [10]. Furthermore, in a murine model,Table 2 Mortality for Parkinsons disease as the underlying ca





All periods 1.33 0.75–21.5 1.03
≤ 10 years 0.60 0.15–1.57 1.78
> 10 years 2.22 1.15–3.80 0.64deprivation of vitamin B12 produced apoptosis of neu-
rons in Substantia Nigra of adult rats and appearance of
a parkinsonian-like phenotype [11].
Isoflurane is metabolized by cytochrome P450 2E1
(CYP2E1); on the other hand CYP2E1 has been detected
in Substantia Nigra Pars Compacta and Striate Nucleus.
Animal studies and in vitro essays on neuronal tissues
suggested that administration of isoflurane increased the
production of reactive oxygen species (ROS), through
enzyme induction of CYP2E1, implicated in the patho-
genesis of PD [12].
Isoflurane anesthesia enhanced extracellular dopamine
concentration through inhibition of dopamine active
transporter (DAT), placed on dopaminergic pre-synapses
[13,14]. The lesser recovery of dopamine from synaptic
spaces involved an increase in: dopamine uptake, dopa-
mine intracellular overload and ROS production at cyto-
solic level [15,16].
Isoflurane can induce neuro-inflammation, as shown by
different studies that found an increase of tumor necrosis
factor (TNF–alfa) and interleukins (IL–6 e IL–1beta) in
the cerebral tissues of rodents [17].
Isoflurane reduced (by facilitating endocytosis) synap-
tic receptors n–methyl–d–aspartate [NMDA] in an ex-
periment in vitro where neurons from healthy mice were
exposed to isoflurane 2% for six hours. There were ensu-
ing changes in excitability of nigrostriatal and corticostria-
tal neurons that greatly reduced cognitive performance
and played a role in the onset of PD [18].
Sevoflurane was found to increase TNF-alfa and pro-
duction of beta-amyloid through activation of caspases
and apoptotic cascade [19], which are major characteris-
tics of PD [20].
Halothane and isoflurane increased cytotoxicity in
pheochromocytoma cells in vitro, by increasing
oligomerization of beta-amyloid. The same mechanism
presents itself at the nigro-striate level producing dopa-
minergic neurotoxicity [21].
Halothane has been shown to be capable of binding
tubulin, altering its polymerization and destroying the
polymerized microtubules [22]; in addition, a recent
study has shown an interaction between the halothane
molecule and the microtubular elements of the neuronal
cytoskeleton [23]. High dose of anesthetics cause anuse of death in two groups of specialized doctors
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pedes the polymerization of the microtubules, thus
determining a lack in macrotubule formation [24].
This evidence suggests a role of anesthetics in the
exacerbation of neurodegenerative illnesses such as PD
[22].Conclusion
The diagnosis of PD in this patient is quite certain since
it is based on a brain SPECT demonstrating a reduced
concentration of a presynaptic radioactive tracer of the
dopaminergic system in the basal ganglia on the right
and in the lenticular basal ganglia on the right and left.
Pollution from anesthetic gases at unacceptable levels
was widespread in public hospitals in the Veneto from
1990 to 1999 (Table 1 and Figure 1) as well as in private
hospitals in the Veneto until at least 2007, as it can be
inferred by overexposure to sevoflurane assessed in the
patient while working in one of these private structures.
The time elapsed from first exposure to anesthetic gases
(1983) to onset of PD symptoms (2005) was 22 years,
fulfilling the induction/latency period of >10 years that
was observed in the US study comparing anesthesiolo-
gists and internists [6].
The hypothesis of association between exposure to
anesthetic gases and PD is recent [5,6] and PD is relatively
rare; both facts explain the few number of epidemiological
studies on the topic. However, the hypothesis of associ-
ation between exposure to anesthetic gases and risk of PD
was strengthened by several recent mechanistic studies
(in vivo short-term studies and in vitro essays) that linked
exposure to anesthetic gases (nitrous oxide, halothane, iso-
flurane, lovoflurane) with PD risk.
In the reported case, moreover, a non-occupational
disease is unlikely because of the absence of: family his-
tory for PD or essential tremor and personal history of
mood disorders [25]; bronchial asthma constipation and
arterial hypertension (or treatment with beta blockers or
calcium channel blockers) [26]; general anesthesia [5].
There was no exposure to pesticides, residency in rural
areas or use of well water contaminated by pesticides
[5,15]. The patient is a smoker and a moderate con-
sumer of coffee and alcohol though these habits are pro-
tective factors against PD [25].
In view of the limited evidence of human studies
and the sufficient evidence of experimental studies,
the high exposure to anesthetic gases could have in-
duced PD in the subject under study. Although add-
itional studies are warranted, this evidence could
enable Health Authorities to appropriately answer
the claims of workers exposed to anesthetic gases,
taking into account scientific evidence and social
expectations.Consent statement
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